Welcome to our dedicated page for Novabay Pharma SEC filings (Ticker: NBY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Stablecoin Development Corporation filings document the company’s completed transition from NovaBay Pharmaceuticals, including its name change, ticker change, and updated public-company identity as an on-chain holding company focused on the Sky protocol ecosystem. Recent 8-K disclosures cover SKY-related activities, staking metrics, operating updates, and material-event reporting.
The company’s SEC filings also describe capital-structure changes, including a reverse stock split, pre-funded warrants, preferred stock conversions, charter amendments, stockholder voting results, and NYSE American-related approvals. Proxy materials and 8-K reports document governance matters, security-holder rights, warrant accounting, non-reliance on prior financial statements, and formal amendments to the company’s corporate documents.
NovaBay Pharmaceuticals (NBY): Schedule 13D/A update — R01 Fund LP, together with related entities and Michael Kazley, reports beneficial ownership of 56,806,080 shares of Common Stock, representing 45.1% of the class. The group reports shared voting and dispositive power over 56,806,080 shares and no sole power.
The reported position is comprised of 220,663 shares of Series D Non-Voting Convertible Preferred Stock (convertible into a maximum of 35,306,080 Common shares) and 134,375 shares of Series E Non-Voting Convertible Preferred Stock (convertible into a maximum of 21,500,000 Common shares). Shares outstanding were 6,010,749 as of October 1, 2025.
On October 15, 2025, the reporting persons entered into a pre-funded warrant to purchase 2,702,703 Common shares. The warrant is not exercisable until January 1, 2026 and is not exercisable in its entirety until stockholders approve issuance of the shares subject to the warrant.
NovaBay Pharmaceuticals (NBY): Schedule 13D/A — Framework Ventures IV L.P. and related reporting persons disclosed beneficial ownership of 56,806,080 shares of Common Stock, representing 45.1% of the class. The filing states shared voting and dispositive power over 56,806,080 shares and no sole power.
The position reflects 220,663 shares of Series D Non‑Voting Convertible Preferred Stock (convertible into a maximum of 35,306,080 common shares) and 134,375 shares of Series E Non‑Voting Convertible Preferred Stock (convertible into a maximum of 21,500,000 common shares). Shares outstanding were 6,010,749 as of October 1, 2025.
Item 6 notes a pre-funded warrant giving the right to purchase 2,702,703 common shares, not exercisable until January 1, 2026 and not exercisable in full until stockholders approve the issuance of those shares.
NovaBay Pharmaceuticals (NBY): Insider transaction disclosed. CEO, Director, and 10% owner Michael Kazley reported indirect acquisitions of preferred shares via the R01 Entities. On 10/16/2025, 220,663 shares of Series D Non-Voting Convertible Preferred Stock and 134,375 shares of Series E Non-Voting Convertible Preferred Stock were acquired at $0.00 per share, held indirectly by R01 Entities.
Each Series D and Series E share converts into 160 common shares following stockholder approvals at the annual meeting on 10/16/2025. The filing lists underlying common share amounts of 35,306,080 for the Series D and 21,500,000 for the Series E. The Series D holdings were purchased pursuant to an agreement dated 10/09/2025, and the Series E rights and obligations were acquired under the same agreement.
NovaBay Pharmaceuticals (NBY) reported an insider transaction on a Form 4 involving Framework Ventures IV L.P. On October 16, 2025, the reporting persons recorded a Transaction Code J relating to preferred stock interests: 220,663 shares of Series D Non‑Voting Convertible Preferred and rights to purchase 134,375 shares of Series E Non‑Voting Convertible Preferred.
Following stockholder approvals at the annual meeting on October 16, 2025, each preferred share is convertible into 160 common shares. The filing lists underlying common shares of 35,306,080 for the Series D and 21,500,000 for the Series E. The Framework entities note potential deemed beneficial ownership and disclaim beneficial ownership except to the extent of pecuniary interest. Ownership is reported as Direct (D).
NovaBay Pharmaceuticals (NBY) insider filing: R01 Fund LP reported acquiring derivative securities tied to common stock. On 10/16/2025, it acquired 220,663 shares of Series D Non‑Voting Convertible Preferred Stock and 134,375 shares of Series E Non‑Voting Convertible Preferred Stock at a stated price of $0.00.
Per the terms approved at the annual meeting on 10/16/2025, each preferred share is convertible into 160 common shares. The Series D corresponds to 35,306,080 underlying common shares and the Series E corresponds to 21,500,000 underlying common shares. The filing notes relationships including director, 10% owner, and officer (Chief Executive Officer) and states the R01 entities’ beneficial ownership is disclaimed except to the extent of pecuniary interest.
NovaBay Pharmaceuticals (NBY) disclosed an insider ownership update. CEO and Director Michael Kazley filed a Form 3 as a 10% owner, reporting indirect beneficial ownership through the R01 Entities of Series D Non‑Voting Convertible Preferred Stock that is convertible into up to 1,164,117 shares of common stock at an exercise price of $0.00.
The filing notes that on October 9, 2025, R01 Fund LP purchased 220,663 shares of Series D Preferred and the rights and obligation to purchase 134,375 shares of Series E Preferred. Following stockholder approval at the annual meeting on October 16, 2025, each share of Series D will automatically convert into 160 common shares at the holder’s option or within three business days, and the Issuer will issue Series E, each share of which will automatically convert into 160 common shares at the holder’s option or within thirty business days.
NovaBay Pharmaceuticals (NBY): Initial insider ownership filed. Framework Ventures IV L.P. and affiliated entities jointly filed a Form 3 disclosing preferred equity positions tied to NovaBay common stock.
On October 9, 2025, Framework LP purchased 220,663 shares of Series D Non-Voting Convertible Preferred Stock, which is convertible into a maximum of 1,164,117 shares of common stock, and acquired rights and obligations to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock.
Following stockholder approval of proposals 5 and 9 at the October 16, 2025 annual meeting, each share of Series D Preferred converts into 160 common shares at the holder’s option or within three business days of the meeting, and each share of Series E Preferred converts into 160 common shares at the holder’s option or within thirty business days. The filing indicates a Director relationship and was submitted jointly pursuant to a Joint Filing Agreement dated October 20, 2025.
NovaBay Pharmaceuticals (NBY) reported a beneficial ownership change by the R01 Entities. On October 9, 2025, R01 Fund LP purchased 220,663 shares of Series D Non‑Voting Convertible Preferred Stock, which is convertible into up to 1,164,117 shares of common stock. The filing lists related reporting persons including R01 Capital LLC, R01 Capital Manager LLC, and Michael Kazley.
Following stockholder approval at the October 16, 2025 annual meeting, each share of Series D Preferred is set to convert into 160 common shares at the holder’s option or within three business days. The filing also notes rights and obligations to purchase 134,375 shares of Series E Preferred, each share of which will convert into 160 common shares at the holder’s option or within thirty business days after the meeting.
NovaBay Pharmaceuticals (NBY) received an amended Schedule 13D from David E. Lazar detailing ownership and recent transactions. As of the close on October 16, 2025, he beneficially owned 1,502,080 shares of common stock, representing 19.99% of the class, based on 6,010,749 shares outstanding as of October 1, 2025 from a recent registration statement.
Lazar reported holding 39,925 shares of Series D Preferred Stock (aggregate purchase price approximately $319,400). On October 9, 2025, he entered a Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P. for the sale of 441,325 Series D Preferred for $9,850,000 and the transfer of rights to purchase 268,750 Series E Preferred for an additional $2,150,000 payable to the company. Required stockholder approvals were obtained at the October 16, 2025 annual meeting. He also resigned as CEO and director, effective upon release of escrow funds.
The preferred stock remains subject to a 19.99% beneficial ownership limitation.
NovaBay Pharmaceuticals (NBY): insider transaction filed on Form 4. David E. Lazar reported the disposition of 441,325 shares of Series D Convertible Preferred Stock on October 16, 2025 (Transaction Code S). The Series D shares are convertible at the holder’s option into common stock at a rate of 160 common shares per preferred share, equating to 70,612,000 underlying common shares.
According to the footnotes, the sale followed an October 9, 2025 Securities Purchase Agreement with R01 Fund LP and Framework Ventures IV L.P., under which the purchasers agreed to acquire the 441,325 Series D shares for $9,850,000 and the rights and obligations to purchase 268,750 shares of Series E Preferred Stock for an additional $2,150,000 payable to the issuer. After the reported transaction, Lazar beneficially owned 39,925 derivative securities.